Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
- Conditions
- Medical Oncology
- Interventions
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT02639091
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
- Conditions
- Gestational Trophoblastic Neoplasms
- Interventions
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Weiguo Lv
- Target Recruit Count
- 214
- Registration Number
- NCT02639650
- Locations
- 🇨🇳
Weiguo Lv, Hangzhou, Zhejiang, China
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Linda R Duska
- Target Recruit Count
- 88
- Registration Number
- NCT02635360
- Locations
- 🇺🇸
Washington University, School of Medicine, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸INOVA Fairfax Hospital, Falls Church, Virginia, United States
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 338
- Registration Number
- NCT02633202
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 87
- Registration Number
- NCT02633800
- Locations
- 🇫🇷
Hopital Croix-Rousse, Lyon, France
🇵🇱Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland
🇧🇪Institut Jules Bordet, Brussels, Belgium
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT02633176
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Tongji Hospital,Tongji Medical College of Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
- Conditions
- Thymoma and Thymic Carcinoma
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1
- Registration Number
- NCT02633514
- Locations
- 🇨🇳
Kailiang Wu, Shanghai, Shanghai, China
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
- Conditions
- CholangiocarcinomaGastrointestinal TumorBiliary CarcinomaGall Bladder Carcinoma
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT02631590
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
- Conditions
- Squamous Cell Carcinoma Head and Neck
- Interventions
- Biological: AlloVax™Drug: Cisplatin
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Mirror Biologics, Inc.
- Registration Number
- NCT02624999
- Locations
- 🇹🇭
National Cancer Institute of Thailand, Bangkok, Thailand
Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 39
- Registration Number
- NCT02624128
- Locations
- 🇮🇹
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.